Sterile injectable drugs are sterile, parenteral preparations containing one more Active Pharmaceutical Ingredient (API) intended for administration into the body.
Growth of the global sterile injectable drugs is primarily driven by increasing demand for novel drug delivery systems, rising prevalence of chronic diseases, increasing public private partnerships and also rising awareness towards the use of sterile injectable drugs.

The global Sterile Injectable Drugs market was valued at US$ 3408 million in 2019 and is expected to reach US$ 4878.9 million by the end of 2026, growing at a CAGR of 5.2% during 2021-2026.
This report focuses on Sterile Injectable Drugs volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Sterile Injectable Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Sterile Injectable Drugs Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
Cytokines
Insulin
Peptide hormones
Vaccines
Immunoglobulins
Blood Factors
Peptide antibiotics
Others

Segment by Application
Cancer
Diabetes
Cardiovascular Diseases
Musculoskeletal
CNS
Infections
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company
Baxter International
Sanofi
GlaxoSmithKline
AstraZeneca
Merck
Novartis
Pfizer
GILEAD SCIENCES
Johnson & Johnson Services